Abstract
Nephropathy is one of the major complications of diabetes which further directs to end stage renal disease. Extensive work has been done to find out the mechanisms involved in pathogenesis of the DN. Now, many researchers have been convinced that almost all of the molecular mediators and intracellular signaling pathways involved in progression of diabetic nephropathy have involvement in transforming growth factor beta (TGF- β) at some stage.
In DN, hyperglycemia causes increase in the expression of TGF- β genes, TGF- β proteins and their receptors. Increased glucose level mediates these effects through activation of polyol pathway, protein kinase C pathway, hexosamine pathway, increases advanced glycation end products (AGE) and increases oxidative stress. Hyperglycemia also activates the TGF- β via activation of glucose transporters (GLUT), angiotensine II and platelet derived growth factor (PDGF). Activated TGF-β further leads to glomerular basement membrane (GBM) thickening and glomerulosclerosis through activation of connective tissue growth factor (CDGF) and vascular endothelial growth factor (VEGF).
We have discussed the progression of hyperglycemia to DN via TGF- β, whose schematic presentation may serve as an effective way to understand the mechanisms and to find out an effective way for the management of diabetic nephropathy.
Keywords: AGE, GBM, glomerulosclerosis, PDGF, protein kinase C, VEGF.
Current Diabetes Reviews
Title:Hyperglycemia to Nephropathy via Transforming Growth Factor Beta
Volume: 10 Issue: 3
Author(s): Mayuresh Sudamrao Garud and Yogesh Anant Kulkarni
Affiliation:
Keywords: AGE, GBM, glomerulosclerosis, PDGF, protein kinase C, VEGF.
Abstract: Nephropathy is one of the major complications of diabetes which further directs to end stage renal disease. Extensive work has been done to find out the mechanisms involved in pathogenesis of the DN. Now, many researchers have been convinced that almost all of the molecular mediators and intracellular signaling pathways involved in progression of diabetic nephropathy have involvement in transforming growth factor beta (TGF- β) at some stage.
In DN, hyperglycemia causes increase in the expression of TGF- β genes, TGF- β proteins and their receptors. Increased glucose level mediates these effects through activation of polyol pathway, protein kinase C pathway, hexosamine pathway, increases advanced glycation end products (AGE) and increases oxidative stress. Hyperglycemia also activates the TGF- β via activation of glucose transporters (GLUT), angiotensine II and platelet derived growth factor (PDGF). Activated TGF-β further leads to glomerular basement membrane (GBM) thickening and glomerulosclerosis through activation of connective tissue growth factor (CDGF) and vascular endothelial growth factor (VEGF).
We have discussed the progression of hyperglycemia to DN via TGF- β, whose schematic presentation may serve as an effective way to understand the mechanisms and to find out an effective way for the management of diabetic nephropathy.
Export Options
About this article
Cite this article as:
Garud Sudamrao Mayuresh and Kulkarni Anant Yogesh, Hyperglycemia to Nephropathy via Transforming Growth Factor Beta, Current Diabetes Reviews 2014; 10 (3) . https://dx.doi.org/10.2174/1573399810666140606103645
DOI https://dx.doi.org/10.2174/1573399810666140606103645 |
Print ISSN 1573-3998 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6417 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Sodium Glucose Co-Transporter 2 Inhibitors: Beyond Glucose Lowering
Current Drug Targets Antioxidant Therapy in Diabetic Complications: What is New?
Current Vascular Pharmacology Epoxyeicosatrienoic Acids as a Therapeutic Target for Nephropathy Associated with Diabetes and Hypertension
Current Hypertension Reviews Reactive Oxygen Species, Inflammation, and Lung Diseases
Current Pharmaceutical Design Role of Chymase in Preeclampsia
Current Vascular Pharmacology Effect of Antioxidant Extract from Cherries on Diabetes
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Medications not Intended for Treatment of Dyslipidemias and with a Variable Effect on Lipids
Current Pharmaceutical Design Low Osteopontin N-Terminal Fragment and Carotid Plaque Stability Associated with Statin or Antiplatelet Therapy
Current Vascular Pharmacology Update on the Biologic Role of the Vitamin D Endocrine System
Current Vascular Pharmacology Diabetic Retinopathy in Pregnancy
Current Diabetes Reviews HSP70 Family in the Renal Inflammatory Response
Inflammation & Allergy - Drug Targets (Discontinued) Current Concepts in the Management of Diabetic Polyneuropathy
Current Diabetes Reviews Disturbance of Inorganic Phosphate Metabolism in Diabetes Mellitus: Its Impact on the Development of Diabetic Late Complications
Current Diabetes Reviews Insulin Resistance in the Early Stages of Renal Failure: Implications for Cardiovascular Risk
Current Diabetes Reviews Chemical Analysis of the Chinese Herbal Medicine Turmeric (Curcuma longa L.)
Current Pharmaceutical Analysis Assessing Cardiovascular Risk in Patients with Diabetes: An Update
Current Cardiology Reviews Prediction and Diagnosis of Post Transplant Diabetes
Current Diabetes Reviews Novel Therapeutic Targets for Phosphodiesterase 5 Inhibitors: current state-of-the-art on systemic arterial hypertension and atherosclerosis
Current Pharmaceutical Biotechnology Cannabidiol as a Putative Novel Therapy for Diabetic Retinopathy: A Postulated Mechanism of Action as an Entry Point for Biomarker-Guided Clinical Development
Current Pharmacogenomics and Personalized Medicine Neuropsychiatric Systemic Lupus Erythematosus
Current Neuropharmacology